Hikma PharmaceuticalsHKMPF +4.28%82 Days Payable is 95.60 as of Dec. 2025, which is 26% above its 10-year median of 75.81. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $26.53 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 920 Drug Manufacturers companies, Hikma Pharmaceuticals ranks worse than 51.41% on this metric.
Hikma Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hikma Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a Days Payable of 95.60 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hikma Pharmaceuticals and its competitors. This is 26% above median its historical median of 75.81. Over the past decade, Hikma Pharmaceuticals' Days Payable has ranged from 54.51 to 91.62. According to the industry distribution chart, Hikma Pharmaceuticals ranks #473 out of 920 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is Hikma Pharmaceuticals' Days Payable too high?
Hikma Pharmaceuticals' current Days Payable of 95.60 is 26% above median its 10-year median of 75.81. Over the past 10 years, this metric has ranged from a low of 54.51 to a high of 91.62. The Drug Manufacturers industry median Days Payable is 90.84. Hikma Pharmaceuticals' value of 95.60 is 5.2% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #473 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #473 out of 920 companies for Days Payable. This places Hikma Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 90.84. Hikma Pharmaceuticals' value of 95.60 is 5.2% above this benchmark. Historically, Hikma Pharmaceuticals' own Days Payable has ranged from 54.51 to 91.62 over the past decade. While the company's 10-year median is 75.81 vs. the industry median of 90.84, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Days Payable of 95.60 is 5.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Days Payable is 95.60, which is 26% above median its own 10-year median of 75.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $26.53, compared to a current price of $20.12 — trading 24.2% below its estimated fair value. The current Days Payable is 95.60, which is 26% above median its 10-year median of 75.81 and 5.2% above the Drug Manufacturers industry median of 90.84. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Days Payable is 95.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.12 is trading 24.2% below its estimated GF Value™ of $26.53.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
Days Payable: 95.60 (26% above median its 10-year median of 75.81)
GF Value™: $26.53 vs. price of $20.12 (24.2% below fair value)
Industry Position: 5.2% above the Drug Manufacturers median (#473 of 920)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
